The DESolve Bioresorbable Coronary Scaffold is a novel drug-eluting device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor, has demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using Elixir's metallic coronary stents. The drug dose is 3 mcg per mm of scaffold length. We aimed to present the IVUS results of the first-in-man evaluation of this novel scaffold. Methods: The DESolve FIM trial enrolled 15 patients, treated with a single 3.0x14 mm DESolve at 3 centers. IVUS was performed at the end of the procedure and repeated at six-month invasive follow-up. Complete and adequate IVUS images at baseline and follow-up were obtained for 11 cases. Serial changes in vessel volume, scaffold area and the degree of NIH formation were assessed. All analyses were performed by an independent core laboratory. ) and % scaffold obstruction (7.18 Ϯ 3.37%). and no cases of incomplete strut apposition.
). Additionally, there was no significant change in vessel volume (from 148.0 Ϯ 37.0 mm 3 to 150.03 Ϯ 35.38 mm 3 ) or area, demonstrating the absence of constrictive or expansive remodelling. There was very low neointimal volume (5.6 Ϯ 2.8 mm 3 ) and % scaffold obstruction (7.18 Ϯ 3.37%). and no cases of incomplete strut apposition.
Conclusions:
The DESolve scaffold demonstrated a unique property of expansion and no chronic recoil from baseline to follow-up. Results at 6 months showed effective neointimal suppression and no late strut malapposition thus suggesting a very efficacious and novel bioresorbable scaffold. Background: Positive vessel remodeling, caused by an increase in peri-stent plaque volume during follow-up, has frequently been demonstrated in clinical studies of paclitaxel-eluting stents (PES). Histopathologic studies have also shown an association of positive remodeling with vessel inflammation, possibly related to the occurrence of very late stent thrombosis. This study aimed to investigate the determinants of vessel remodeling in patients treated with PES as assessed by IVUS. Methods: Serial (post-procedure and 8-9 months follow-up) volumetric IVUS data were analyzed in 227 de novo coronary lesions electively treated with PES. Volume index (VI) was defined as volume/length (mm 3 /mm). Peri-stent plaque VI was standardized by stent VI (%PVI). Vessel remodeling during follow-up was assessed as a change of peri-stent plaque VI per stent VI. Morphologic properties with a p-valueϽ0.10 on univariate analysis were inserted into multivariate models. Results: Overall, the change of vessel VI during follow-up was 5.0Ϯ8.1% (range: -21.7% to ϩ36.1%), resulted from a significant increase of %PVI (95.9Ϯ29.9% to 103.9Ϯ28.9%, pϽ0.0001). Among IVUS parameters at post-procedure, vessel VI and %PVI had significant inverse correlations with positive vessel remodeling (pϭ0.002, pϭ0.0002, respectively). In multivariate analysis, less %PVI at post-procedure was independently associated with positive vessel remodeling during follow-up (pϭ0.02). Conclusions: This pooled IVUS analysis identified thinner peri-stent plaque surrounding PES at baseline as a predictor of larger positive vessel remodeling during follow-up. This may reflect the differential mechanical compliance and/or increased drug infiltration into the deep vessel wall structure in the setting of less underlying plaque behind the stent. Background: It is unknown whether IVUS utilization during percutaneous coronary intervention (PCI) may modify the stent length effect on clinical outcomes. We sought to find differential prognostic impact of intravascular ultrasound (IVUS) utilization according to the implanted stent length. Methods: Between April 2008, and June 2010, we enrolled 3244 consecutive patients underwent single or overlapping stent implantation at 46 academic or community hospitals in Korea. The primary endpoint was a composite of death, myocardial infarction, or target vessel revascularization (MACE). Study population was divided by the tertiles of implanted stent length and IVUS utilization. Results: After adjustment for significant covariates, implanted stent length was not significantly associated with the risk of MACE in IVUS group (hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.97-1.20, pϭ0.16), whereas implanted stent length was significantly associated with the risk of MACE in no IVUS group (HR 1.13, 95% CI 1.01-1.28, pϭ0.042). In addition, in patients with implanted stent length of Յ22mm (Nϭ998), the risk of MACE was not significantly different between IVUS group and no IVUS group (HR 1.06, 95% CI 0.50-2.28, pϭ0.88). By contrast, in patients with longer implanted stent length, the risk of MACE was significantly lower in IVUS group than in no IVUS group (HR 0.47, 95% CI 0.24-0.92, pϭ0.027 for 23-32mm [Nϭ1109] , HR 0.57, 95% CI 0.33-0.98, pϭ0.042 for Ն33mm [Nϭ1137]). Conclusions: IVUS utilization may attenuate the detrimental effect of the increase of implanted stent length, supporting the favor of IVUS utilization, particularly during PCI with the long stent implantation.
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